Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has secured separate marketing approvals from China’s National Medical Products Administration (NMPA) for its biosimilars of Novo Nordisk (NYSE: NVO)’s Tresiba (insulin degludec) and Ryzodeg (insulin degludec and insulin aspart), both of which are indicated for the treatment of type 2 diabetes.
These approvals mark the introduction of the first biosimilar versions of these products in China, demonstrating comparable clinical efficacy and safety to the original formulations. This development positions Sihuan to capitalize on the growing demand for diabetes treatments in the Chinese market.- Flcube.com
